Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma (Q27851979)

From Wikidata

Jump to navigation Jump to search

scientific article

• Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

edit

Language	Label	Description	Also known as
English	Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma	scientific article	Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

Statements

instance of

scholarly article

1 reference

stated in

PubMed

PubMed publication ID

23213094

retrieved

13 November 2016

title

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma (English)

1 reference

stated in

PubMed

PubMed publication ID

23213094

retrieved

13 November 2016

main subject

biomarker

0 references

patient

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

author

Keith Flaherty

series ordinal

16

object named as

Keith T Flaherty

0 references

Toni K Choueiri

series ordinal

1

object named as

Toni K Choueiri

0 references

author name string

Ulka Vaishampayan

series ordinal

2

0 references

Jonathan E Rosenberg

series ordinal

3

0 references

Theodore F Logan

series ordinal

4

0 references

Andrea L Harzstark

series ordinal

5

0 references

Ronald M Bukowski

series ordinal

6

0 references

Brian I Rini

series ordinal

7

0 references

Sandy Srinivas

series ordinal

8

0 references

Mark N Stein

series ordinal

9

0 references

Laurel M Adams

series ordinal

10

0 references

Lone H Ottesen

series ordinal

11

0 references

Kevin H Laubscher

series ordinal

12

0 references

Laurie Sherman

series ordinal

13

0 references

David F McDermott

series ordinal

14

0 references

Naomi B Haas

series ordinal

15

0 references

Robert Ross

series ordinal

17

0 references

Peter Eisenberg

series ordinal

18

0 references

Paul S Meltzer

series ordinal

19

0 references

Maria J Merino

series ordinal

20

0 references

Donald P Bottaro

series ordinal

21

0 references

W Marston Linehan

series ordinal

22

0 references

Ramaprasad Srinivasan

series ordinal

23

0 references

language of work or name

English

0 references

publication date

10 January 2013

0 references

published in

Journal of Clinical Oncology

0 references

volume

31

0 references

issue

2

0 references

page(s)

181-6

0 references

cites work

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

20 March 2017

Cancer statistics, 2010

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

20 March 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

20 March 2017

A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

29 September 2017

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

29 September 2017

Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

29 September 2017

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

29 September 2017

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

29 September 2017

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

29 September 2017

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

29 September 2017

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

29 September 2017

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

2 June 2018

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

2 June 2018

Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

27 November 2018

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

27 November 2018

Declaration of Helsinki. Ethical principles for medical research involving human subjects.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

27 November 2018

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

27 November 2018

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390

retrieved

27 November 2018

Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23213094

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Papillary renal tumors. Morphologic, cytochemical, and genotypic features

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23213094

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23213094

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1200/JCO.2012.43.3383

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3362164

OpenCitations bibliographic resource ID

3362164

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3362164

PMC publication ID

3532390

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3362164

PubMed publication ID

23213094

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3362164

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851979&oldid=1951060156"